Effects of the Contraceptive Implant in Women With Sickle Cell Disease

Running, not enrolling · Phase 4

Conditions studied: Sickle Cell Disease

In brief

The objective of this study is to measure the acceptability and impact of the progestin implant on frequency of vaso-occlusive crises, quality of life, and hematologic parameters in women with SCD.

Key facts

Study ID

NCT05730205

Run by

University of Pennsylvania

People needed

22

Starts

2023-08-02

Expected to finish

2027-03-01

Last updated by the study team

2026-06-12

Who can join

Age: 18 and older, up to 45. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female aged 18-45
• Diagnosis of sickle cell disease (SS, SB 0, SB+, SC)
• Report of at least 1 vaso-occlusive pain episode per month on average in the previous 6 months
• Willing to discontinue any hormonal contraception at the time of enrollment. Washout period of 1 month required for all hormonal contraception prior to enrollment in the study.
• Access to a device with text messaging capability
• Must be able to read and understand English
• Willing to comply with study procedures

You may not qualify if…

• Use of Depo Provera in the past 6 months
• Changes to sickle cell medications in the past 3 months
• Regular blood transfusions
• History of hematopoeitic stem cell transplantation
• Contraindications to use of Nexplanon device as per clinical standards (not including history of venous thromboemblosim [VTE])
• Currently pregnant or pregnant within the last month or seeking to become pregnant
• Currently breastfeeding

Where it is running

• Penn Medicine University City — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.